# Giant cell tumour of the larynx—a diagnostic challenge

## TL;DR

Giant cell tumors in the larynx are rare and challenging to diagnose, often requiring surgery or denosumab treatment to manage effectively.

## Contribution

The paper presents a case study of a young adult with a supraglottic mass, contributing to the limited clinical understanding of this rare condition.

## Key findings

- GCTs of the larynx are rare, with only 44 reported cases, and often present as a palpable neck mass.
- Surgery is the preferred treatment, but denosumab is a viable alternative for high-risk cases.
- Accurate diagnosis requires histology after surgery due to the broad differential diagnosis.

## Abstract

Giant cell tumours (GCTs) of the larynx are extremely rare. The most affected structure is the thyroid cartilage and only 44 cases are reported in the literature.1 Clinically, their first manifestation is usually a palpable neck mass, often accompanied by hoarseness, dyspnoea, and/or dysphagia depending on size and location. GCTs are benign neoplasms, yet awareness of this entity is crucial as their aggressive local behaviour can cause significant morbidity with airway obstruction and can simulate a malignancy. The differential diagnosis is broad and remains a clinical and radiological challenge. Indeed, the final diagnosis is established by histology postoperatively. Surgery is the preferred treatment but may impair voice quality. For incomplete surgical resections and high surgical risk lesions, denosumab treatment is a valuable option. We share our experience on GCTs in a young adult presenting as a supraglottic mass.